Caricamento...
Developing EZH2 Targeted Therapy for Lung Cancer
Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown anti-tumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinomas models expressing high levels of EZH2 (1).
Salvato in:
| Pubblicato in: | Cancer Discov |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5012289/ https://ncbi.nlm.nih.gov/pubmed/27587466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0800 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|